The Motley Fool Discussion Boards
Stocks E / Exelixis, Inc.
|Subject: GDC-0973 - Exelixis hidden gem||Date: 9/19/2012 2:32 AM|
|Author: marsuculix||Number: 463 of 664|
hi fellow Fools,
as promised, here my next post regarding Exelixis
GDC-0973, Genetech/Roche's potent, selective MEK1/2 inhibitor, is used in combination with a PI3K inhibitor in the treatment of solid tumors.
Interesting fact: GDC-0973 is also known as XL-518 (originally developped by Exelixis !). See reference here:
At ESMO 2012 there will be a pivotal latebreaker presentation - LBA28 - of a phase-I trial; as this information is embargoed, the results will be available on Saturday, Sep 29, 2012, 9:15 am (Vienna time)the earliest.
I intend to make the conclusion of this latebreaker available to you asap., since I plan to attend this session
It looks like Exelixis has another hot iron in the forge...
take care, marsuculix
(I am a molecular biologist and consultant to Swiss pharmaceutical companies - I will try to dig a hole to my former university colleagues working @ Roche - may be it pays off)
|Copyright 1996-2015 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us|